Renaissance Capital logo

OBLN News

US IPO Weekly Recap: Another tech IPO pops in a week with 6 IPOs

COUP

Six companies went public, making it the year's second most-active week. Coupa Software was the latest software IPO to price above its range and pop on the first day (+85%) as IPO investors continue to embrace high growth and strong margins, offered at a discount to public peers. Three large PE-backed IPOs also traded up this week (12% on average), while the week's two smallest...read more

Obalon Therapeutics prices IPO at $15, within the range

OBLN

Obalon Therapeutics, which is commercializing an intragastric balloon device designed to assist with weight loss, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Obalon Therapeutics plans to list on the Nasdaq under the symbol OBLN. UBS Investment Bank, Canaccord Genuity and Stifel acted as lead managers on the deal....read more

US IPO Week Ahead: Seven deals slotted to raise $1 billion total

FMAX

Coming off a strong end to the third quarter, October is set to get off to a quick start with seven deals on the calendar in the week ahead. Investors will undoubtedly be paying close attention to the next notable tech deal, Coupa Software (COUP), which comes on the heels of strong third quarter performance for tech deals (+66% on average) and...read more

Medical device company Obalon Therapeutics sets terms for $75 million IPO

OBLN

Obalon Therapeutics, which is developing an intragastric medical device to assist with weight loss, announced terms for its IPO on Monday. The Carlsbad, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $20 million worth of shares in the offering. At the midpoint of the proposed range, Obalon...read more